| 余进闽,张春容,王 丹,刘小庆,余剑霞.银杏内酯注射液联合阿托伐他汀钙片对急性脑梗死患者神经功能、血脂、抗氧化能力和TLR4/NF-κB信号通路的影响[J].,2022,(17):3351-3355 |
| 银杏内酯注射液联合阿托伐他汀钙片对急性脑梗死患者神经功能、血脂、抗氧化能力和TLR4/NF-κB信号通路的影响 |
| Effects of Ginkgolide Injection Combined with Atorvastatin Calcium Tablet on Neurological Function, Blood Lipid, Antioxidant Capacity and TLR4/NF-?资B Signaling Pathway in Patients with Acute Cerebral Infarction |
| 投稿时间：2022-03-19 修订日期：2022-04-15 |
| DOI：10.13241/j.cnki.pmb.2022.17.030 |
| 中文关键词: 银杏内酯注射液 阿托伐他汀钙片 急性脑梗死 神经功能 血脂 抗氧化能力 TLR4/NF-κB信号通路 |
| 英文关键词: Ginkgolide injection Atorvastatin calcium tablet Acute cerebral infarction Nerve function Blood lipid Antioxidant capacity TLR4/NF-κB signaling pathway |
| 基金项目:2019年重庆市教委科学技术研究项目（KJQN201900420） |
|
| 摘要点击次数: 717 |
| 全文下载次数: 310 |
| 中文摘要: |
| 摘要 目的：探讨银杏内酯注射液联合阿托伐他汀钙片对急性脑梗死（ACI）患者神经功能、血脂、抗氧化能力和Toll样受体4（TLR4）/核因子-κB（NF-κB）信号通路的影响。方法：选择2019年6月~2020年6月期间来重庆医科大学附属永川医院接受治疗的152例ACI患者，采用随机数字表法分为两组，分别为研究组（n=76），接受银杏内酯注射液联合阿托伐他汀钙片治疗；对照组（n=76），接受阿托伐他汀钙片治疗。两组均治疗14 d，对比两组疗效、神经功能情况、血脂、抗氧化能力和TLR4/NF-κB信号通路变化情况，观察两组用药安全性。结果：研究组的临床总有效率明显高于对照组（P<0.05）。两组治疗后美国国立卫生院神经功能缺损评分（NIHSS）、神经元特异烯醇化酶（NSE）、S100β蛋白下降，且研究组低于对照组（P<0.05）。两组治疗后总胆固醇（TC）、低密度脂蛋白（LDL-C）、甘油三酯（TG）下降，且研究组低于对照组（P<0.05），两组高密度脂蛋白（HDL-C）升高，且研究组高于对照组（P<0.05）。两组治疗后过氧化氢酶（CAT）、超氧化物歧化酶（SOD）、总抗氧化能力（TAC）升高，且研究组高于对照组（P<0.05）。两组治疗后血清TLR4、NF-κB水平下降，且研究组低于对照组（P<0.05）。两组不良反应发生率组间对比无差异（P>0.05）。结论：银杏内酯注射液联合阿托伐他汀钙片治疗ACI，有利于减轻神经功能损伤，调节血脂，提高抗氧化能力，可能与调节TLR4/NF-κB信号通路有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of ginkgolide injection combined with atorvastatin calcium tablet on neurological function, blood lipid, antioxidant capacity and and toll-like receptor 4 (TLR4)/nuclear factor -κB (NF-κB) signaling pathway in patients with acute cerebral infarction. Methods: A total of 152 patients with ACI who received treatment in Yongchuan Hospital Affiliated to Chongqing Medical University from June 2019 to June 2020 were selected and divided into two groups by random number table method: study group (n=76), who received Ginkgolide injection combined with atorvastatin calcium tablet. The control group (n=76) received atorvastatin calcium tablet. Both groups were treated for 14 days. The efficacy, nerve function, blood lipid, antioxidant capacity and TLR4/NF-κB signaling pathway changes were compared between the two groups, and the safety of medication was observed. Results: The total clinical effective rate of the study group was significantly higher than that of the control group (P<0.05). After treatment, national Institutes of Health neurological deficit score (NIHSS), neuron specific enolase (NSE) and S100β protein decreased in both groups, and the study group was lower than the control group (P<0.05). After treatment, total cholesterol (TC), low density lipoprotein (LDL-C) and triglyceride (TG) in both groups decreased, and the study group was lower than the control group (P<0.05), while high density lipoprotein (HDL-C) in both groups increased, and the study group was higher than the control group (P<0.05). After treatment, catalase (CAT), superoxide dismutase (SOD) and total antioxidant capacity (TAC) in both groups increased, and the study group was higher than the control group (P<0.05). After treatment, the levels of TLR4 and NF-κB in both groups decreased, and the study group was lower than the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Ginkgolide injection combined with atorvastatin calcium tablets in the treatment of ACI is beneficial to reduce nerve function injury, regulate blood lipid and improve antioxidant capacity, which may be related to the regulation of TLR4 / NF-κB signal pathway. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
